PT 2385

Drug Profile

PT 2385

Alternative Names: PT-2385

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer Peloton Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Renal cell carcinoma
  • Preclinical Glioblastoma; Von Hippel-Lindau disease

Most Recent Events

  • 06 Dec 2016 Preclinical trials in Glioblastoma in USA (PO) before December 2016
  • 06 Dec 2016 Preclinical trials in Von Hippel-Lindau disease in USA (PO) before December 2016
  • 06 Jun 2016 Initial positive efficacy, pharmacodynamic and adverse events data from a phase I trial in Renal cell carcinoma presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top